Bristol-Myers Squibb Company (NYSE:BMY) Director Theodore R. Samuels II bought 6,000 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The stock was acquired at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the purchase, the director now owns 18,000 shares in the company, valued at approximately $1,006,920. The purchase was disclosed in a legal filing with the SEC, which is available at this link.
Bristol-Myers Squibb Company (NYSE:BMY) traded up 0.25% on Friday, hitting $56.73. 4,060,530 shares of the stock traded hands. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $61.30. The firm has a market cap of $93.03 billion, a price-to-earnings ratio of 20.72 and a beta of 1.17. The stock has a 50-day moving average of $55.80 and a 200-day moving average of $54.64.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter in the prior year, the company posted $0.69 EPS. The business’s revenue was up 5.6% on a year-over-year basis. Analysts forecast that Bristol-Myers Squibb Company will post $2.97 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, August 1st. Stockholders of record on Friday, July 7th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is 56.73%.
WARNING: This piece was originally reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.baseball-news-blog.com/2017/08/14/bristol-myers-squibb-company-bmy-director-acquires-335640-00-in-stock-updated.html.
Several institutional investors have recently made changes to their positions in BMY. Union Bankshares Corp boosted its position in shares of Bristol-Myers Squibb by 12.2% in the first quarter. Union Bankshares Corp now owns 4,405 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 480 shares in the last quarter. Norges Bank acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $770,318,000. Doyle Wealth Management acquired a new position in shares of Bristol-Myers Squibb during the first quarter worth about $14,571,000. Philadelphia Trust Co. boosted its position in shares of Bristol-Myers Squibb by 7.7% in the fourth quarter. Philadelphia Trust Co. now owns 20,924 shares of the biopharmaceutical company’s stock worth $1,223,000 after buying an additional 1,500 shares in the last quarter. Finally, Numeric Investors LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $1,671,000. Institutional investors own 69.79% of the company’s stock.
A number of equities analysts have recently commented on the stock. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 target price on the stock. in a research note on Wednesday. BidaskClub raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Monday, June 26th. Finally, BMO Capital Markets downgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a research note on Wednesday, May 3rd. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $62.12.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.